Novartis MS Drug Kesimpta Quick Out Of The Blocks

There is plenty of room for B-cell therapies to grow in the multiple sclerosis space and while Roche Holding AG's Ocrevus is a formidable arrival, Novartis AG's just-launched Kesimpta "ticks the boxes" of high efficacy, a clean safety profile and convenient administration which will convert the drug into a blockbuster.

That is the view of Norman Putzki, head of neuroscience development at Novartis who recently reflected on the launch and future prospects for Kesimpta (ofatumumab) in an interview with Scrip....